Optimizing vaccine design (antigen and adjuvant selection), concentrating on the role of CD4 + T cells in tumor vaccines, and utilizing combination immunotherapy will be new keys to increasing the efficacy of GBM vaccines. Here, CD4 is linked to glioblastoma.